Guardant Health, Northwestern University Collaborate
News Nov 25, 2016
Guardant Health has announced that it has signed a deal with Northwestern University making Guardant360 the preferred liquid biopsy test for patients with advanced cancer treated at Northwestern's Robert H. Lurie Comprehensive Cancer Center.
Guardant said that the agreement also covers multiple large-scale prospective clinical trials in which researchers at the Lurie center will use its technology. Lurie Center Director Leonidas Platanias said in a statement that Lurie's growing OncoSET (Sequence, Evaluate, Treat) program will benefit from Guardant Health's non-invasive technology.
On the research side, every patient evaluated within the Lurie Cancer Center OncoSET Program will be enrolled in one of several prospective clinical trials exploring additional clinical uses of liquid biopsy, Guardant said. The partners also plan to track the outcomes of patients whose treatment selection was guided by Guardant360.
"This collaboration will help us determine the value of prospective molecular monitoring in patients with advanced disease by exploring the potential of liquid biopsy specifically, and precision oncology in general, to impact lives," added Northwestern's Massimo Cristofanilli, director of the OncoSET program.
Source: Story from Guardant Health. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE